Journal of the American Society of Hypertension
Volume 1, Issue 3 , Pages 169-177, May 2007

Large arteries and the kidney

  • Michel E. Safar, MD

      Affiliations

    • Faculty of Medicine, Paris Descartes University, Paris, France
    • Diagnosis Center, Hôtel-Dieu Hospital (AP-HP), Paris, France
    • Corresponding Author InformationCorresponding author: Michel E. Safar, MD, Diagnosis Center, Hôpital Hôtel-Dieu, 1, place du Parvis Notre-Dame, 75181 Paris Cedex 04, France. Tel: 00-33-1-42-34-80-25; fax: 00-33-1-42-34-86-32.
  • ,
  • Tewfik Nawar, MD

      Affiliations

    • Department of Medicine (Nephrology), University of Sherbrooke, Québec, Canada
  • ,
  • Gérard E. Plante, MD, PhD

      Affiliations

    • Department of Medicine (Nephrology), University of Sherbrooke, Québec, Canada
    • Department of Physiology, University of Sherbrooke, Québec, Canada
    • Department of Pharmacology, University of Sherbrooke, Québec, Canada
    • Institute of Geriatrics, University of Sherbrooke, Québec, Canada

Received 29 November 2006; accepted 28 February 2007.

Abstract 

In subjects with chronic renal disease, high systolic blood pressure (SBP) is the most modifiable cardiovascular (CV) risk factor that enables prevention of the progression of chronic kidney disease renal failure and the occurrence of CV events. Although large-artery stiffness and wave reflections are the principal hemodynamic determinants of SBP, their precise role in the progression of chronic renal disease has been poorly investigated. However, in subjects with mild to severe renal insufficiency, increased arterial stiffness and reduced creatinine clearance are closely related, independently of age; mean arterial pressure level; and presence of other traditional risk factors, including atherosclerotic plaques. Through inflammatory mechanisms, as well as through the development of arterial calcifications (including microscopic) and sodium-related alterations in extracellular matrix composition, arterial stiffness is associated with significant SBP and increased pulse pressure (PP). In the presence of renal dysfunction, frequently observed in elderly hypertensive or diabetic subjects, or even in some living donors, the resulting increase in PP may be transmitted toward and across glomeruli, even when peripheral blood pressure values are maintained. This alteration alone may initiate glomerulosclerosis and/or tubulointerstitial damage, eventually leading to CV events. In subjects with end-stage renal disease and high CV risk, pharmacological modulation of the renin–angiotensin system has been shown to prevent independently such complications.

Keywords: Chronic renal disease, hypertension, arterial stiffness

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by INSERM (Institut de la Santé et de la Recherche Médicale), GPH-CV (Groupe de Pharmacologie et d’Hémodynamique Cardiovasculaire), Paris, and FRSQ (Fonds de la Recherche en Santé du Québec). The authors thank Dr. Anne Safar for helpful and stimulating discussions.Conflict of interest: none.

PII: S1933-1711(07)00062-9

doi:10.1016/j.jash.2007.02.007

Journal of the American Society of Hypertension
Volume 1, Issue 3 , Pages 169-177, May 2007